Cocrystal Pharma Inc. (COCP)
COCP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1412486/000149315222007551/0001493152-22-007551-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | COCP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001412486 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2020
| Line | Value |
|---|---|
| Revenue | $2.0M |
| Net income | -$9.6M |
| Operating income | -$9.6M |
| Net margin | -479.0% |
| Operating margin | -476.0% |
| Revenue growth | -69.3% |
| Cash | $33.0M |
| Total assets | $54.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-08-13 |
| Cash and burn | $2.2M cash; operating cash flow -$2.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 19,263,200 (2026-08-13); 10,258,866 a year earlier; 10,173,790 three years earlier. | Cover page 2026-08-13 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-04-23 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Weinberg & Company, P.A., Los Angeles, California, United States | PCAOB Form AP 2026-04-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $301K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $105K | -$3.2M | -$2.5M | $2.2M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $225K | -$2.3M | -$2.3M | $4.7M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | Not filed | -$2.4M | -$1.7M | $7.0M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$2.0M | -$1.4M | $7.7M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$2.1M | -$2.2M | $4.8M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$2.3M | -$2.9M | $6.9M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2024 2024-12-31 | Not filed | -$3.3M | -$3.2M | $9.9M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$4.9M | -$5.1M | $13.1M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-04-23 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-09-09 |
| Latest proxy | DEFA14A | 2026-05-27 |
Source: SEC EDGAR submissions feed, 674 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.8% |
| 1 month | -9.3% |
| 3 months | -10.9% |
| Year to date | 0.0% |
| 1 year | -4.9% |
| From 52-week high | -37.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ATOS | Atossa Therapeutics Inc. | $1.93 | -1.53% | $19.3M |
| LPCN | Lipocine Inc. | $1.66 | -2.92% | $18.4M |
| AYTU | Aytu BioPharma Inc. | $1.82 | +1.68% | $19.8M |
| CELU | Celularity Inc. | $0.6191 | -1.75% | $20.1M |
| SHPH | Shuttle Pharmaceuticals Holdings Inc. | $4.24 | -6.40% | $20.2M |
| IGC | IGC Pharma Inc. | $0.1750 | -0.57% | $20.4M |
| CPHI | China Pharma Holdings Inc. | $0.4800 | -7.35% | $20.7M |
| QNRX | Quoin Pharmaceuticals Ltd. | $3.56 | -3.78% | $17.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier